Barclays PLC Acquires 347,692 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Barclays PLC grew its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 192.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 528,629 shares of the biotechnology company's stock after buying an additional 347,692 shares during the quarter. Barclays PLC owned 0.22% of ADMA Biologics worth $10,567,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. CWM LLC boosted its stake in ADMA Biologics by 114.2% during the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company's stock valued at $92,000 after purchasing an additional 4,367 shares during the last quarter. Calamos Advisors LLC grew its holdings in ADMA Biologics by 8.3% during the second quarter. Calamos Advisors LLC now owns 603,003 shares of the biotechnology company's stock worth $6,742,000 after buying an additional 46,405 shares in the last quarter. Bank of New York Mellon Corp raised its position in ADMA Biologics by 6.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 766,544 shares of the biotechnology company's stock valued at $8,570,000 after buying an additional 49,631 shares during the last quarter. Viewpoint Capital Management LLC lifted its stake in ADMA Biologics by 32.4% during the 2nd quarter. Viewpoint Capital Management LLC now owns 20,416 shares of the biotechnology company's stock valued at $228,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in ADMA Biologics by 5.4% during the 2nd quarter. Rhumbline Advisers now owns 310,539 shares of the biotechnology company's stock worth $3,472,000 after acquiring an additional 15,844 shares during the last quarter. 75.68% of the stock is owned by institutional investors.

Insider Buying and Selling

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the company's stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares in the company, valued at $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 3.70% of the stock is currently owned by corporate insiders.

ADMA Biologics Stock Performance

NASDAQ:ADMA traded down $0.35 on Tuesday, reaching $18.63. 1,637,727 shares of the company's stock were exchanged, compared to its average volume of 3,567,883. The firm has a market cap of $4.40 billion, a price-to-earnings ratio of 67.32 and a beta of 0.70. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The stock has a fifty day simple moving average of $19.00 and a 200-day simple moving average of $16.16. ADMA Biologics, Inc. has a 52 week low of $4.06 and a 52 week high of $23.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million during the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same period in the previous year, the business earned $0.01 EPS. As a group, sell-side analysts predict that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

Analysts Set New Price Targets

ADMA has been the topic of a number of recent analyst reports. Cantor Fitzgerald reissued an "overweight" rating and set a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th. Raymond James lifted their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research report on Friday, November 8th. Finally, HC Wainwright upped their target price on ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a report on Friday, November 8th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.